Market Cap : 4.71 B | Enterprise Value : 5.13 B | PE Ratio : At Loss | PB Ratio : 8.84 |
---|
NAS:GH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:GH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Guardant Health's Capital Expenditure for the three months ended in Mar. 2022 was $-22.70 Mil. Its Operating Income for the three months ended in Mar. 2022 was $-123.34 Mil.
GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.
The historical data trend for Guardant Health's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Guardant Health's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Guardant Health's Capex-to-Operating-Income falls into.
Guardant Health's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2021 is calculated as
Capex-to-Operating-Income | = | - Capital Expenditure | / | Operating Income |
= | - (-75.035) | / | -411.001 | |
= | N/A |
Guardant Health's Capex-to-Operating-Income for the quarter that ended in Mar. 2022 is calculated as
Capex-to-Operating-Income | = | - Capital Expenditure | / | Operating Income |
= | - (-22.7) | / | -123.338 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Thank you for viewing the detailed overview of Guardant Health's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Talasaz Amirali | director, officer: Chairman, President and COO | 18 ISABELLA AVENUE ATHERTON CA 94027 |
Kaul Samir | director | C/O KHOSLA VENTURES 3000 SAND HILL ROAD, BLDG. 3, SUITE 170 MENLO PARK CA 94025 |
Meresman Stanley J | director | 2071 HUNTINGTON LANE LOS ALTOS CA 94024 |
Svf Bluebird (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Svf Enterprise (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Sb Investment Advisers (uk) Ltd | 10 percent owner | 69 GROSVENOR STREET LONDON X0 W1K 3JP |
Softbank Vision Fund (aiv M1) L.p. | 10 percent owner | 251 LITTLE FALLS DRIVE WILMINGTON DE 19808 |
Svf Endurance (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Clark Ian T | director | SOLAZYME, INC. 225 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080 |
Eltoukhy Helmy | director, officer: Chief Executive Officer | 2 BARRY LANE ATHERTON CA 94027 |
Bertocci Derek A | officer: Chief Financial Officer | 3070 ORCHARD DRIVE SAN JOSE CA 95134 |
Saia John G. | officer: See Remarks | C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY CA 94063 |
Gadde Vijaya | director | C/O TWITTER INC 1355 MARKET STREET SUITE 900 SAN FRANCISCO CA 94103 |
Jallal Bahija | director | 120 MONUMENT CIRCLE INDIANAPOLIS IN 46204 |
Nishar Dipchand | director | C/O LINKEDIN CORPORATION 2029 STIERLIN COURT MOUNTAIN VIEW CA 94043 |
From GuruFocus
Other Sources
By Zacks 2021-07-29
By Fool 2022-03-08
By Zacks 2022-02-11
By Zacks 2021-11-03
By Zacks 2021-11-04
By Zacks 2021-07-19
By tipranks.com 2022-03-10
By Fool 2022-04-01
By Zacks 2021-07-30
By Zacks 2021-08-05
By Fool 2021-10-01
By Zacks 2022-01-28
By tipranks.com 2022-04-05